Equities research analysts expect CareDx Inc (NASDAQ:CDNA) to post earnings of ($0.13) per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for CareDx’s earnings. The lowest EPS estimate is ($0.15) and the highest is ($0.11). CareDx also posted earnings of ($0.13) per share in the same quarter last year. The firm is expected to announce its next earnings results on Friday, April 20th.
Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for CareDx.
CareDx (NASDAQ:CDNA) last issued its quarterly earnings results on Thursday, November 9th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.02. CareDx had a negative return on equity of 157.00% and a negative net margin of 84.14%. The business had revenue of $12.19 million for the quarter, compared to the consensus estimate of $12.05 million. The company’s quarterly revenue was down 2.3% compared to the same quarter last year.
In related news, COO Mitchell J. Nelles sold 10,948 shares of CareDx stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $7.17, for a total transaction of $78,497.16. Following the completion of the sale, the chief operating officer now owns 84,225 shares of the company’s stock, valued at $603,893.25. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider James P. Yee sold 29,197 shares of CareDx stock in a transaction on Friday, December 8th. The shares were sold at an average price of $7.00, for a total value of $204,379.00. Following the sale, the insider now directly owns 74,795 shares of the company’s stock, valued at approximately $523,565. The disclosure for this sale can be found here. 5.40% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Private Wealth Partners LLC boosted its position in CareDx by 2,250.0% during the third quarter. Private Wealth Partners LLC now owns 235,000 shares of the company’s stock valued at $869,000 after purchasing an additional 225,000 shares during the last quarter. Gagnon Securities LLC boosted its position in CareDx by 3.9% during the third quarter. Gagnon Securities LLC now owns 2,166,403 shares of the company’s stock valued at $8,016,000 after purchasing an additional 82,111 shares during the last quarter. Thompson Davis & CO. Inc. boosted its position in CareDx by 3,294.9% during the third quarter. Thompson Davis & CO. Inc. now owns 203,692 shares of the company’s stock valued at $754,000 after purchasing an additional 197,692 shares during the last quarter. Perkins Capital Management Inc. acquired a new stake in CareDx during the third quarter valued at $513,000. Finally, Royce & Associates LP boosted its position in CareDx by 8.1% during the third quarter. Royce & Associates LP now owns 792,787 shares of the company’s stock valued at $2,933,000 after purchasing an additional 59,500 shares during the last quarter. 23.36% of the stock is owned by hedge funds and other institutional investors.
Shares of CareDx (NASDAQ CDNA) traded up $0.07 during mid-day trading on Tuesday, hitting $5.83. The stock had a trading volume of 93,693 shares, compared to its average volume of 242,785. CareDx has a twelve month low of $0.76 and a twelve month high of $7.98. The company has a quick ratio of 0.35, a current ratio of 0.55 and a debt-to-equity ratio of -124.53. The stock has a market capitalization of $169.05, a P/E ratio of -3.19 and a beta of 0.70.
CareDx Company Profile
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.